KURA Kura Oncology, Inc.

10.40
+0  (1%)
Previous Close 10.30
Open 10.45
Price To book 3.50
Market Cap 201.21M
Shares 19,347,000
Volume 55,964
Short Ratio 3.77
Av. Daily Volume 65,777

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 first dosing announced January 17, 2016.
Tipifarnib
Chronic myelomonocytic leukemia (CMML) - cancer
Phase 2 top-line data due 1H 2017.
Tipifarnib
Relapsed or refractory peripheral T-cell lymphoma
Phase 2 ongoing data released March 6, 2017 - further data due 2H 2017.
Tipifarnib
HRAS mutant solid tumors - cancer
Phase 2 dosing commenced June 2016. Top-line data due 2H 2017.
Tipifarnib
Lower risk myelodysplastic syndromes (MDS) - cancer